INTRODUCTION {#SEC1}
============

Single nucleotide variants (SNVs) are responsible for ∼90% of human variability ([@B1]). When mapped on coding regions (single amino acid variants, SAVs) may affect the function of the transcribed proteins ([@B2]), leading to phenotype variations, and often to pathology. Last generation sequencing and genotyping techniques are reporting a large amount of human genetic variation data ([@B3]), fueling initiatives to derive links between genome alterations and pathologies. Thus, the HapMap consortium ([@B4]) is characterizing common variation and linkage disequilibrium patterns that can be related to common diseases ([@B5]). The Human Variation Project ([@B6]) collects, curates, and makes accessible information on genetic variations affecting human health. The 1000 Genomes Project ([www.1000genomes.org](http://www.1000genomes.org)) is expected to produce the most complete catalog of genetic variations in human population ([@B7]). Already in 2005, the Wellcome Trust Case Control Consortium genotyped ∼14 000 patients for seven common diseases performing one of the largest Genome-Wide Association Study (GWAS) ([@B8]) to date. As a result of these and other projects the dbSNP database at the NCBI ([@B9]) collects, nowadays, ∼20 million of validated human SNPs. The manually curated SwissVar database ([@B10]) reports on the pathological effect of ∼61 000 missense SNPs, the public version of the HGMD database ([@B11]) includes \>78 000 missense mutations causing, or associated with human inherited diseases, plus disease-associated/functional polymorphisms and ClinVar reports over 125 000 clinically relevant variants ([@B12]). Systematic sequencing through NGS of cancer patients (projects like ICGC, [www.icgc.org](http://www.icgc.org), and TGCA, [cancergenome.nih.gov](http://cancergenome.nih.gov)) expanded the range of mutations in the human genome. For example, the present public version of ICGC reports ∼520 000 new somatic SAVs.

Despite the amount of data available, the issue of predicting the functional consequences of SAVs is still open, and there is a continuous effort in developing more accurate and flexible predictors ([@B13]--[@B15]). There is no consensus on the type of approach used to obtained predictions. PMUT ([@B16]), one of the oldest and still widely used methods, uses neural networks, as so does for instance SNAP ([@B17]); SIFT ([@B18]), Polyphen ([@B19]), PROVEAN ([@B20]), LRT ([@B21]) and MutationAssessor (22; Hidden Markov Models are used in PANTHER ([@B23]) and FATHMM ([@B24]); Random Forests are used in PON-P2 ([@B25]), CHASM ([@B26]), CanPredict ([@B27]) and MuD ([@B28]); Support Vector Machines in CADD ([@B29]), SNPs&GO ([@B30]), SeqProfCod ([@B31]), LS-SNP ([@B32]), SNPs3D ([@B33]), MetaSVM ([@B34]) and MetaLR ([@B34]); Naïve Bayes is used in MutationTaster ([@B35]), and a gradient boosting tree is used in M-CAP ([@B36]). Also predictors giving consensus predictions like Condel ([@B37]), are available. All of them use input features that represent the change in amino acid sequence, structure and evolutionary properties resulting from the amino acid replacement.

PMut ([@B16]), first released in 2005, predicted the pathological nature of a given SAV, and also hot-spot positions on protein sequences. PMut used a neural network-based classifier trained by a manually curated dataset extracted from SwissProt ([@B38]), and used sequence conservation and predicted physico-chemical properties as main features. Here, we present a major update of the PMut predictor and web portal. While maintaining the philosophy of the original application, the backend classification engine has been completely renewed and automated, taking advantage of the increase in the amount of data available for training. The engine powering PMut is provided as a separate software package (PyMut) that allows users to prepare their own predictors for specific families of proteins. The new PMut web site also provides access to a complete data repository, including all possible SAVs on human known proteins. The web portal is available at <http://mmb.irbbarcelona.org/PMut> and has already received more than 900 requests between 1 January 2017 and 1 April 2017.

PMut PREDICTION ENGINE {#SEC2}
======================

PMut prediction engine (PyMut) is prepared as a Python 3 module. PyMut is based on the widely used libraries NumPy ([www.numpy.org](http://www.numpy.org)) and Scipy ([www.scipy.org](http://www.scipy.org)), for fast numerical computing, Pandas (data management, [pandas.pydata.org](http://pandas.pydata.org)), Scikit-learn (machine learning, [scikit-learn.org](http://scikit-learn.org)), Matplotlib ([matplotlib.org](http://matplotlib.org)), and Seaborn (graphical representation, [seaborn.pydata.org](http://seaborn.pydata.org)). PyMut performs all operations regarding calculation of features, selection of classifiers, validation and results analysis. It is distributed as a separate software module that can be downloaded and installed locally. Specific functions available are: Compute protein features and plot their distribution (see [Supplementary Tables S1 and S2](#sup1){ref-type="supplementary-material"} in the Supplementary Material for a complete list, and details of the procedures).Select the most informative features. Selection of features is performed in an iterative way, following the improvement of MCC obtained in cross-validation. [Supplementary Figure S1](#sup1){ref-type="supplementary-material"} shows a schema of the algorithm used, and [Supplementary Figure S2](#sup1){ref-type="supplementary-material"} a plot of such MCC evolution.Train classifiers, evaluate them using several cross-validation protocols, and obtain their Receiver Operating Characteristic (ROC) curves (see [Supplementary Table S4](#sup1){ref-type="supplementary-material"}, and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"} for a list of the available classifiers and its comparative performance).Prepare and evaluate a pathology predictor.Predict the pathology of mutations.

PyMut module covers all operations required to generate new predictors in a fully automated way (see [Supplementary Table S5](#sup1){ref-type="supplementary-material"} for a detailed list of software functions, and [Supplementary Table S6](#sup1){ref-type="supplementary-material"} for a list of software dependencies), allowing the user to easily explore alternative datasets, classifiers or collections of features, enabling to fine tune the predictor to cover not only pathology, but other structural or functional characteristics of the proteins. As the module can be downloaded and run locally, it allows the user to analyze private data to derive tailored predictors without uploading it to a server.

PyMut source code is available at <https://github.com/inab/pymut> and in the official Python package repository (<https://pypi.python.org/pypi/pymut>), and can be downloaded from the PMut Web portal, where a tutorial following the main functions of PyMut is also available.

PMut2017 PREDICTOR {#SEC3}
==================

PMut2017 default predictor was trained using the manually curated variation database SwissVar ([@B10]) (October 2016 release), which contains 27 203 disease and 38 078 neutral mutations on 12 141 proteins. Two hundred fifteen numerical features were first computed for each mutation, accounting for (i) physical property differences between wild type and mutated amino acids, (ii) protein interactome information and (iii) amino acid conservation. The conservation features are derived from local searches over UniRef100 and UniRef90 cluster databases ([@B39]), using PSI-Blast ([@B40]), and multiple sequence alignments generated using Kalign2 ([@B41]). After evaluation of the different machine learning algorithms ([Supplementary Table S4](#sup1){ref-type="supplementary-material"} and [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), the chosen predictor is based on a Random Forest ([@B42]) classifier, trained with only 12 selected features (see [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). The classifier outputs a prediction score between 0 and 1; mutations scoring from 0 to 0.5 are classified as neutral, and those scoring from 0.5 to 1 are classified as pathological. To evaluate the confidence degree of such score, we have analyzed the accuracy of the predictions based on their score ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). It can be seen that accuracy increases with extreme score values. The analysis of these results allows us to qualify the prediction with a statistically meaningful reliability score.

PMut predictor has been validated following several approaches: *A traditional 10-fold cross-validation on protein families with 50% sequence identity exclusion*. No sequence in the testing set shares \>50% sequence identity with any protein in the training set. Figure [1](#F1){ref-type="fig"} shows the corresponding ROC curves. Detailed performance metrics are summarized in Table [1](#tbl1){ref-type="table"}. Restriction of the analysis to most confident predictions lead to a significant increase in the performance of the prediction. See [Supplementary Figure S4](#sup1){ref-type="supplementary-material"} for a measured confidence of PMut scores.*A blind validation using new SwissVar entries*. To perform this analysis, PMut has been trained using the same protocol, but limited to the data available at the SwissVar December 2015 release, and tested with SwissVar 2016 entries (3166 new mutations on 762 proteins. 1656 mutations were tagged as pathological and 1510 as neutral). For comparative purposes, we have also performed a complete series of analyses of the same test-set using other prediction methods. Table [2](#tbl2){ref-type="table"} shows the good performance of PMut when applied to the entire test set. The new engine used in PMut2017 represents a large improvement over the original PMut predictor (MCC 0.03 in the blind validation, data not shown). If predictions are limited to those cases where more reliable scores are obtained (PMut 85%), MCC value raises to 0.53, what puts PMut as the most accurate predictor within the test performed, covering yet \>80% of the mutations. This can be further improved taking only \>90% confidence scores (MCC 0.62), but in this case predictions can be obtained only in half of the cases. The availability of PyMut module allows for a seamless update of PMut predictor when new releases of SwissVar become available.*A blind validation using ClinVar entries not included in the training set*. ClinVar ([@B12]) is an alternative well known source for disease related variants. ClinVar includes a much larger set of variants, although only 34 024 can be directly mapped to the protein sequences used in PMut. From those, 13 716 were already present in the SwissVar training set. To further analyze the performance of the PMut2017 predictor we have analyzed the variants reported in ClinVar that were not used in the training set (20 308 variants). Results are shown in Table [2](#tbl2){ref-type="table"}. MCC value (0.49) is slightly better but comparable with those obtained in the SwissVar 2016 delta release. This behavior further confirms the prediction power of PMut2017.*Comparative test on selected genes*. Global validation schemas provide an averaged estimation of the performance of a prediction method. Applying the predictor to specific protein families may result in a degraded performance due to the individual features of such families. We have selected a number of genes to evaluate PMut2017 performance in comparison with some other methods. To avoid a statistical bias, genes have been selected in a way that the number of neutral and pathological mutations were equilibrated and reasonably large. Results are reported in Table [3](#tbl3){ref-type="table"}. As expected, MCC values obtained are specific to the analyzed gene and range widely around the average value obtained in the global test. Although some of them show a clearly poorer result, it can be seen that the behavior is consistent with the other methods assayed, and shows a good predicting power. These differences additionally support the need to develop specific predictors for protein families showing non-standard behavior.

![ROC Curves corresponding to PMut2017 10-fold cross-validation based on protein families. No sequence in the validation set has more than 50% identity with sequences in the training set. Additional curves correspond to the subsets of prediction with 85% and 90% confidence. AUC: area under the curve, MCC: Matthews Correlation Coefficient.](gkx313fig1){#F1}

###### Summary of performance metrics for PMut2017 predictor

  Confidence   Coverage   Accuracy   Sensitivity   Specificity   AUC    MCC
  ------------ ---------- ---------- ------------- ------------- ------ ------
  All          100        0.82       0.76          0.86          0.81   0.62
  \>85% ^a^    85.9       0.85       0.75          0.92          0.83   0.69
  \>90% ^a^    64.9       0.90       0.80          0.95          0.87   0.77

^a^Only predictions with scores corresponding to higher confidence levels are considered (see [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

###### Comparative performance of PMut2017 predictor

  Method                          Coverage (%)   Accuracy   Specificity   Sensitivity   AUC        MCC
  ------------------------------- -------------- ---------- ------------- ------------- ---------- ----------
  SIFT ([@B18])                   89.6           0.61       0.33          0.88          0.60       0.25
  Polyphen2 ([@B19])              92.1           0.64       0.35          0.91          0.63       0.32
  PROVEAN ([@B20])                91.5           0.64       0.41          0.87          0.64       0.31
  FATHMM ([@B24])                 90.5           0.55       0.45          0.64          0.55       0.09
  PON-P2 ([@B25])                 42.4           0.72       0.52          0.9           0.71       0.45
  CADD ([@B29])                   95.0           0.65       0.33          0.94          0.64       0.35
  M-CAP ([@B36])                  91.5           0.60       0.19          0.95          0.57       0.22
  Condel ([@B37])                 91.0           0.63       0.40          0.84          0.62       0.26
  LRT ([@B21])^a^                 95.1           0.73       0.58          0.87          0.73       0.47
  MutationAssessor ([@B22]) ^a^   95.1           0.63       0.46          0.78          0.62       0.26
  MetaSVM ([@B34]) ^a^            95.1           0.63       0.51          0.74          0.62       0.26
  MetaLR ([@B34]) ^a^             95.1           0.6        0.46          0.73          0.60       0.20
  MutationTaster ([@B35]) ^a^     95.1           0.65       0.31          0.96          0.64       0.36
  **PMut**                        **100.0**      **0.71**   **0.65**      **0.76**      **0.71**   **0.42**
  **PMut (85%)^b^**               **81.0**       **0.76**   **0.76**      **0.77**      **0.76**   **0.53**
  **PMut (90%)^b^**               **51.2**       **0.81**   **0.78**      **0.84**      **0.81**   **0.62**
  **PMut (ClinVar)^c^**           **100.0**      **0.73**   **0.88**      **0.85**      **0.75**   **0.49**

Blind validation based on new variants added to SwissVar during 2016 (3166 variants), CADD predictor has been evaluated using a threshold of 20. AUC: area under the ROC curve, MCC: Matthews correlation coefficient.

^a^Analysis performed from ANNOVAR data ([@B42]).

^b^Analysis restricted to most reliable PMut predictions (reliability level in parentheses).

^c^Blind validation based on variants reported on ClinVar ([@B43]), not present in the SwissVar dataset (20,308 variants). Indicated coverage is calculated on ClinVar dataset.

###### Comparative performance of the PMut2017 predictor on selected genes

  Gene                      Disease                                   \#D   \#N   PMut       SIFT    Polyphen   LRT    Mut. Taster   Mut. Assessor   PROVEAN
  ------------------------- ----------------------------------------- ----- ----- ---------- ------- ---------- ------ ------------- --------------- ---------
  **MECP2**                 Rett syndrome                             46    22    **0.86**   0.66    0.85       0.69   0.64          0.41            0.53
  **COL1A2**                Osteogenesis Imperfecta                   78    20    **0.77**   0.74    0.62       0.55   0.55          0.74            0.74
  **SLC4A1**                Distal Renal Tubular Acidosis             38    36    **0.69**   0.65    0.65       0.54   0.55          0.68            0.60
  **ADAMTS13**              Upshaw-Schulman syndrome                  43    17    **0.62**   0.76    0.46       0.00   0.71          0.54            0.62
  **ATM**                   Hereditary cancer-predisposing syndrome   46    54    **0.60**   0.53    0.57       0.32   0.42          0.48            0.55
  **ATP7B**                 Wilson disease                            195   25    **0.48**   0.34    0.49       0.37   0.43          0.29            0.52
  **MLH1+MSH2+MSH6+PMS2**   Lynch syndrome                            159   78    **0.48**   0.32    0.31       0.23   0.16          0.43            0.32
  **MYOC**                  Primary open angle glaucoma               57    24    **0.47**   0.37    0.45       0.38   0.50          0.47            0.49
  **TTC21B**                Jeune thoracic dystrophy                  16    28    **0.42**   0.20    0.22       0.18   0.16          0.28            0.26
  **SCN5A**                 Brugada syndrome                          154   46    **0.40**   0.32    0.26       0.43   0.31          0.34            0.34
  **KCNH2+SCN5A**           Congenital long QT syndrome               270   54    **0.38**   0.32    0.28       0.36   0.32          0.30            0.38
  **ABCA1**                 Tangier disease                           32    31    **0.37**   0.43    0.31       0.32   0.47          0.43            0.47
  **PKHD1+PKD1**            Polycystic kidney disease                 197   96    **0.37**   0.43    0.37       0.30   0.41          0.36            0.45
  **FBN1**                  Marfan syndrome                           385   20    **0.35**   0.31    0.25       0.21   0.33          0.32            0.30
  **RYR1**                  Central core disease                      147   25    **0.34**   0.27    0.31       0.00   0.36          0.28            0.34
  **LDLR**                  Familial hypercholesterolemia             103   23    **0.32**   0.29    0.08       0.17   0.09          0.26            0.25
  **DYSF**                  Limb-Girdle Muscular Dystrophy            48    16    **0.31**   0.35    0.27       0.15   0.21          0.41            0.39
  **BRCA2**                 Breast-ovarian cancer, familial 2         43    61    **0.31**   0.10    0.18       0.18   0.14          0.19            0.01
  **BRCA1**                 Breast-ovarian cancer, familial 1         27    36    **0.31**   0.24    0.20       0.38   0.29          0.30            0.17
  **WFS1**                  WFS1-Related Spectrum Disorders           40    17    **0.30**   0.25    0.35       0.20   0.18          0.16            0.26
  **PINK1**                 Parkinson Disease                         23    39    **0.25**   0.33    0.48       0.40   0.41          0.44            0.30
  **LRRK2**                 Parkinson Disease                         21    24    **0.19**   0.06    0.14       0.01   0.13          0.09            0.14
  **CFTR**                  Cystic fibrosis                           146   32    **0.15**   0.06    0.20       0.21   0.12          0.20            0.27
  **PROC**                  Thrombophilia                             36    28    **0.12**   -0.15   -0.08      0.07   0.14          0.08            -0.01

MCC values obtained restraining the analysis to variants on the indicated genes. Analysis for non-PMut methods performed from ANNOVAR data ([@B42]). \#N Neutral mutations, \#D Disease causing mutations.

PMut WEB PORTAL {#SEC4}
===============

The access to PMut is possible through a Web portal (<http://mmb.irbbarcelona.org/PMut/>) which is implemented in Python using the Django Web framework ([www.djangoproject.com](http://www.djangoproject.com)). The variants' features and predictions are stored in a MongoDB database ([www.mongodb.com](http://www.mongodb.com)). All calculations are performed under the control of a SGE queuing system configured to deploy additional backend workers on peaks of demand. Id mapping and keyword searches are performed using the appropriate services at EBI ([www.ebi.ac.uk](http://www.ebi.ac.uk)). Sequences, features, variants and 3D structures are obtained from MMB-IRB data repository ([mmb.irbbarcelona.org/api](http://mmb.irbbarcelona.org/api)). Most functionalities of the portal are available anonymously, but the users may register to keep records of the activity in the server. After registering, a private workspace is created with links to the prediction requests, and to their customly trained predictors.

The portal is divided in four sections: *Data repository*, which allows the user to access the set of pre-calculated PMut2017 predictions covering all human protein sequences in UniRef100. Search options available include protein name and id (UniprotKB ([@B44]) or PDB ([@B45])), gene id (Ensembl ([@B46])), dbSNP id ([@B9]) and free keywords. Data in the repository can be accessed programmatically through a REST API. The repository is continuously updated with new information appearing in UniRef100 ([@B39]). Detailed statistics of the repository can be found in Table [4](#tbl4){ref-type="table"}.*Pathology prediction*, which allows the user to evaluate the pathological profile of SAVs, input options include protein id(s), or uploaded sequences. PMut Data Repository is used to speed up analysis in the case of known protein sequences. The default predictor is PMut2017, but Custom Predictors can also be used. In the case of mutations mapping on known sequences all possible single SAVs are precomputed. The output includes a variety of graphical and numerical results which are presented in different formats. In all cases, the output combines the information with known variants and sequence features of the protein, giving a comprehensive context of the mutations. When 3D structure is available, the mutations are also mapped onto the structure, using a JsMol visualizer ([www.jmol.com](http://www.jmol.com)). Several public databases (UniprotKB ([@B44]), PDB ([@B45]), PFam ([@B47]), InterPro ([@B48]) and Interactome3D ([@B49])) are linked to the results card. All intermediate data including alignments and calculated features, are available for download in the appropriate formats. See representative screenshots at Help pages on PMut portal, <http://mmb.irbbarcelona.org/PMut/help>).*Batch predictions*, users requesting larger series of predictions can send them in a single batch. The options available, and output are equivalent to single requests. The user is informed when the work is finished and results are stored in his/her private workspace.*Train you own predictor*, this section provides a frontend to the PyMut engine. Users can specify a training set, select a classifier and a validation procedure. Figure [2](#F2){ref-type="fig"} shows some screenshots of the output. Available information includes the original training set, a graphical view of the calculated features (Figure [2A](#F2){ref-type="fig"}), and a summary of the evaluation results (Figure [2B](#F2){ref-type="fig"}). The newly trained predictor becomes automatically available in the prediction section of the portal. Please note that the use of trained predictors requires to log in the personal workspace and is restricted to the user developing it.

![Partial screenshots of output of Predictor\'s training section. (**A**) Comparative plot of the selected protein features. (**B**) ROCs curves of performance evaluation.](gkx313fig2){#F2}

###### Statistics of PMut repository (January 2017)

  Proteins available (from human UniRef)             106 407
  -------------------------------------------------- -------------------
  Analysed variants                                  725 596 928
  Analysed variants (\>85% prediction reliability)   586 383 428 (80%)
  Analysed variants (\>90% prediction reliability)   370 444 279 (51%)

CONCLUSIONS {#SEC5}
===========

The 2017 new release of the PMut portal constitutes a novel approach that largely improves our previous 2005 PMut server. The new portal offers not only a generally trained predictor that performs in a competitive manner with current available methods, but allows the user to access an automatic procedure to train new predictors with specific datasets or features. The possibility of enriching the analysis with alternative predictors, or training predictors with specific information of a single protein family, largely increases the scope of usability of the portal. Overall, the 2017 release of PMut is a powerful tool to approach the issue of predicting functional consequences of protein sequence variants, and will surely contribute to improve the quality of the annotation of pathological variants. The server and platform are already available and accessible without restrictions.

Supplementary Material
======================
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